You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Boehringer Ingelheim
Express Scripts
McKinsey

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,951,131

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,951,131
Title:Sinus delivery of sustained release therapeutics
Abstract: The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.
Inventor(s): Eaton; Donald J. (Los Altos, CA), Moran; Mary L. (Woodside, CA), Brenneman; Rodney A. (San Juan Capistrano, CA)
Assignee: Intersect ENT, Inc. (Palo Alto, CA)
Application Number:12/883,079
Patent Claims: 1. A method for delivering a drug-releasing implant into a paranasal sinus cavity comprising: a) loading a delivery device with one or more drug-releasing implants; b) creating access to the paranasal sinus cavity with the loaded delivery device such that at least a portion of the delivery device is advanced into the paranasal sinus cavity; and c) delivering the one or more drug-releasing implants from the delivery device-into the paranasal sinus cavity, wherein the one or more drug-releasing implants comprise a therapeutic amount of an active agent for the treatment of sinusitis.

2. The method of claim 1 wherein the one or more drug-releasing implants is a solid implant having a first delivery form for facilitating delivery into the sinus cavity and a second form, different from the first form, the second form having a shape that substantially prevents clearance of the implant from the sinus cavity.

3. The method of claim 1 wherein the one or more drug-releasing implants has a diameter of about 5 millimeters while in the conduit.

4. The method of claim 1 wherein delivering the one or more drug-releasing implants comprises delivering the one or more drug-releasing implants with a pusher.

5. The method of claim 1 wherein delivering the one or more drug-releasing implants comprises delivering the one or more drug-releasing implants with a pressurized gas.

6. The method of claim 1 wherein the one or more drug-releasing implants is a biodegradable polymeric implant.

7. The method of claim 1 wherein the delivery device Comprises a conduit.

8. The method of claim 1 wherein a distal portion of the delivery device is angulated.

9. The method of claim 8 wherein the distal portion of the delivery device is angulated at an angle between about zero degrees to about 135 degrees.

10. The method of claim 7 wherein the conduit comprises a distal opening at a tip of the conduit.

11. The method of claim 7 wherein the conduit comprises a distal opening in a side wall of the conduit.

12. The method of claim 1 wherein the one or more drug-releasing implants comprises a series of predetermined fracture lines.

13. The method of claim 1 wherein the one or more drug-releasing implants comprises a therapeutic amount of an anti-inflammatory active agent.

14. The method of claim 13 wherein the anti-inflammatory active agent comprises mometasone furoate.

15. The method of claim 13 wherein the anti-inflammatory active agent comprises budesonide.

16. The method of claim 13 wherein the anti-inflammatory active agent comprises fluticasone propionate.

17. The method of claim 13 wherein the anti-inflammatory active agent comprises triamcinolone acetonide.

18. The method of claim 1 wherein the one or more drug-releasing implants comprises a biodegradable matrix.

19. The method of claim 18 wherein the biodegradable matrix comprises a biodegradable polymer matrix.

20. The method of claim 19 wherein the biodegradable polymer matrix comprises a mucoadhesive polymer.

21. The method of claim 19 wherein the biodegradable polymer matrix comprises a poly(lactic-co-glycolic)acid (PLGA) copolymer.

22. The method of claim 19 wherein the biodegradable polymer matrix comprises lactic acid.

23. The method of claim 19 wherein the biodegradable polymer matrix comprises glycolic acid.

24. The method of claim 1 wherein the active agent is released over a treatment period of about one week to about three months.

25. The method of claim 1 wherein the active agent is released over a treatment period of about two weeks to about four weeks.

26. The method of claim 1 wherein the active agent is released over a treatment period of at least about one week.

27. The method of claim 1 wherein the active agent is released over a treatment period of at least about two weeks.

28. The method of claim 1 wherein the one or more drug-releasing implants comprises an active agent in an amount between about 5% and about 90% by weight of the one or more drug-releasing implants.

29. The method of claim 1 wherein the one or more drug-releasing implants is a rod, pellet, bead, strip, or microparticle.

30. The method of claim 1 wherein creating access to the paranasal sinus cavity comprises puncturing a sinus wall of the paranasal sinus.

31. A method for delivering a drug-releasing implant into a paranasal sinus cavity comprising: a) loading a delivery device with one or more drug-releasing implants; b) creating access to the paranasal sinus cavity with the loaded delivery device such that at least a portion of the delivery device is advanced into the paranasal sinus cavity; and c) delivering the one or more drug-releasing implants from the delivery device-into the paranasal sinus cavity, wherein the one or more drug-releasing implants comprise a therapeutic amount of an active agent for the reduction of inflammation.

32. The method of claim 31 wherein creating access to the paranasal sinus cavity comprises puncturing a sinus wall of the paranasal sinus.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
AstraZeneca
Mallinckrodt
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.